DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Hepatitis Drugs Market - Drivers, Opportunities, Trends, and Forecasts: 2017-2023" report to their offering.
The Hepatitis Drugs Market to Grow at a CAGR of 15.0% During the Forecast Period 2017-2023 to Aggregate $78.67 Billion By 2023
Factors such as rise in injection drug users, increase in awareness, presence of unmet need, and anticipated launch of new drugs are expected to drive the market growth during the forecast period. The market is witnessing the emerging trend of pediatric combination vaccines, which protect against multiple causative agents and thereby reduce the costs gain in packaging and administering individual vaccines. The markets in India, Brazil, China, and Russia are also expected to grow at a rapid pace during the forecast period as the prevalence of hepatitis in these countries is high.
The major drivers of the hepatitis drugs market include the second generation DAAs of Olysio and Sovaldi. Second generation DAAs are more efficacious and have lesser adverse effects. Currently, the market players are developing IFN therapies for the treatment of Hepatitis C. These therapies are intended to be all-oral regimens. The HCV drugs segment comprised more than 84% of the total market share in 2016. A major focus in this segment is expected to drive the growth of the hepatitis drugs market in the future.
Market Dynamics
Drivers
- Increasing Demand of Hepatitis Drugs
- Focus on Advanced DAAs
- Introduction of IFN-free Therapies
- Growth of Injection Drug Users
Restraints
- Long Approval Process and Stringent Regulations
- Side Effects of Hepatitis Drugs
- Increase in the Number of Generic Drugs
- Increasing Market Competition
Opportunities
- Significant Increase in Mergers and Acquisitions
- Emergence of Combination Drugs
- Preventive Healthcare
- Focus of Companies on Emerging Market
Key Players:
- Gilead Sciences Inc.
- Abbvie Inc.
- Johnson & Johnson
- Merck & Co. Inc.
- GlaxoSmithKline plc
- Vertex Pharmaceuticals Inc
- Novartis AG
- Hoffmann-La Roche Ltd
For more information about this report visit http://www.researchandmarkets.com/research/gwgm9r/global_hepatitis
